Feasibility Study for Repurposing RET Inhibitors

Conditions

• Cachexia-Anorexia Syndrome

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Selpercatinib — DRUG
  Patients will be instructed to take selpercatinib orally (PO) twice daily (BID), approximately every 12 hours. While on study, they will undergo weight measurements and regular blood draws every 4 weeks. At the 16-week post-treatment follow-up, patients will return to the clinic for a weight assessment to evaluate potential changes in body weight. Patients will be administered assessments including, Functional Assessment of Anorexia Cachexia Therapy (FAACT), administered at screening, at 12 weeks post-discontinuation of the study drug, and again at the 16-week follow-up.
• Strength Assessment — OTHER
  Several strength assessment will be conducted at baseline and at 12 weeks end-of-treatment, which will include measurements such as grip strength, hallux strength, timed chair stands, leg press, and localized ultrasound of the quadriceps.

Study Details

The purpose of this study is to assess the effects of selpercatinib on cachexia and anorexia in patients diagnosed with NSCLC, colorectal cancer, or pancreatic cancer.

Key Dates

Start date

Feb 26, 2026

Status verified

Jan 2026

Primary completion

Feb 23, 2027

Completion

Feb 23, 2028

Study Design

Enrollment

7 participants (estimated)

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Significant Weight Loss
  Patients will be weighed at baseline, 4, 8, and 12 weeks while on treatment and again at the 16-weeks after treatment has been discontinued to asses for changes in weight.

Primary Outcome Measure

Mean (± SD) changes in body weight after 12 weeks [ Time Frame: 12 weeks ]

Central Contacts

• Lead Onco Nurse
  405-271-8777
  [email protected]
• Nirmal Choradia, MD
  [email protected]

Locations (1)

Find similar trials in Oklahoma City, OK